- Current report filing (8-K)
06 March 2010 - 3:08AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 5,
2010
MARTEK BIOSCIENCES CORPORATION
(Exact name of registrant as specified in its
charter)
Delaware
|
|
0-22354
|
|
52-1399362
|
(State or other jurisdiction of
|
|
(Commission File
|
|
(I.R.S. Employer
|
incorporation or organization)
|
|
Number)
|
|
Identification No.)
|
6480 Dobbin Road, Columbia
Maryland
|
|
21045
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone
number, including area code:
(410) 740-0081
(Former name or former address, if changed
since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
INFORMATION TO BE INCLUDED IN THE
REPORT
Item
7.01 Regulation FD Disclosure.
Attached hereto as Exhibit 99.1
and incorporated herein by reference are slides to be used by Martek
Biosciences Corporation for investor presentations.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit No.
|
|
|
99.1
|
|
Martek Biosciences
Corporation investor presentation slides
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Martek Biosciences Corporation
|
|
|
Date:
March 5, 2010
|
By:
|
/s/
Peter L. Buzy
|
|
|
Peter L. Buzy
|
|
|
Chief Financial Officer, Treasurer and Executive
Vice President for Finance and Administration
|
3
Exhibit Index
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Martek Biosciences
Corporation investor presentation slides
|
4
Martek (NASDAQ:MATK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Martek (NASDAQ:MATK)
Historical Stock Chart
From Jul 2023 to Jul 2024